- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT05921994
Pitkäaikainen havainnollinen, tulevaisuuden monikeskustutkimus, jonka tarkoituksena on kerätä tietoja secukinumAb:n hoitokuviosta aikuispotilailla, joilla on kohtalainen tai vaikea hidradenitis suppurativa. (ANIMA)
Pitkäaikainen havainnointi, tulevaisuuden monikeskustutkimus, jossa kerätään tietoja secukinumAb:n hoitokuviosta aikuispotilailla, joilla on keskivaikea tai vaikea hidradenitis suppurativa (HS) (ANIMA)
The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
The study will collect data from patients during routine secukinumab treatment and will be representative of the real-world patient population eligible for secukinumab treatment in Germany.
In order to attain widespread representation of health care practices related to the use of secukinumab in the approved indication of moderate to severe HS, a broad spectrum of dermatology practices and clinics who are treating patients with HS across Germany will be included.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Aachen, Saksa, 52064
- Novartis Investigative Site
-
Ahaus, Saksa, 48683
- Novartis Investigative Site
-
Annaberg-Buchholz, Saksa, 09456
- Novartis Investigative Site
-
Bad Steben, Saksa, 95138
- Novartis Investigative Site
-
Baden-Baden, Saksa, 76530
- Novartis Investigative Site
-
Berlin, Saksa, 12159
- Novartis Investigative Site
-
Berlin, Saksa, 13595
- Novartis Investigative Site
-
Bielefeld, Saksa, 33647
- Novartis Investigative Site
-
Bochum, Saksa, 44791
- Novartis Investigative Site
-
Bonn, Saksa, 53105
- Novartis Investigative Site
-
Brandenburg, Saksa, 14776
- Novartis Investigative Site
-
Bremen, Saksa, 28359
- Novartis Investigative Site
-
Buxtehude, Saksa, 21614
- Novartis Investigative Site
-
Bückeburg, Saksa, 31675
- Novartis Investigative Site
-
Chemnitz, Saksa, 09117
- Novartis Investigative Site
-
Chemnitz, Saksa, 09113
- Novartis Investigative Site
-
Cologne, Saksa, 51065
- Novartis Investigative Site
-
Delitzsch, Saksa, 04509
- Novartis Investigative Site
-
Dessau, Saksa, 06847
- Novartis Investigative Site
-
Dorsten, Saksa, 46282
- Novartis Investigative Site
-
Dortmund, Saksa, 44137
- Novartis Investigative Site
-
Dresden, Saksa, 01309
- Novartis Investigative Site
-
Düren, Saksa, 52349
- Novartis Investigative Site
-
Emsdetten, Saksa, 48282
- Novartis Investigative Site
-
Erlangen, Saksa, 91054
- Novartis Investigative Site
-
Falkenberg, Saksa, 04895
- Novartis Investigative Site
-
Falkensee, Saksa, 14612
- Novartis Investigative Site
-
Freising, Saksa, 85354
- Novartis Investigative Site
-
Geilenkirchen, Saksa, 52511
- Novartis Investigative Site
-
Gera, Saksa, 07548
- Novartis Investigative Site
-
Gernsbach, Saksa, 76593
- Novartis Investigative Site
-
Gladbeck, Saksa, 45964
- Novartis Investigative Site
-
Großenhain, Saksa, 01558
- Novartis Investigative Site
-
Hamburg, Saksa, 20246
- Novartis Investigative Site
-
Hamburg, Saksa, 22143
- Novartis Investigative Site
-
Hanover, Saksa, 30159
- Novartis Investigative Site
-
Haslach im Kinzigtal, Saksa, 77716
- Novartis Investigative Site
-
Hofgeismar, Saksa, 34369
- Novartis Investigative Site
-
Jena, Saksa, 07743
- Novartis Investigative Site
-
Jülich, Saksa, 52428
- Novartis Investigative Site
-
Karlsruhe, Saksa, 76133
- Novartis Investigative Site
-
Kempen, Saksa, 47906
- Novartis Investigative Site
-
Lübeck, Saksa, 23538
- Novartis Investigative Site
-
Magdeburg, Saksa, 39120
- Novartis Investigative Site
-
Magdeburg, Saksa, 39104
- Novartis Investigative Site
-
Mainz, Saksa, 55116
- Novartis Investigative Site
-
Marburg, Saksa, 35043
- Novartis Investigative Site
-
Minden, Saksa, 32429
- Novartis Investigative Site
-
Mönchengladbach, Saksa, 41063
- Novartis Investigative Site
-
Neu Wulmstorf, Saksa, 21629
- Novartis Investigative Site
-
Nuremberg, Saksa, 90419
- Novartis Investigative Site
-
Oberasbach, Saksa, 90522
- Novartis Investigative Site
-
Oelde, Saksa, 59302
- Novartis Investigative Site
-
Peitz, Saksa, 03185
- Novartis Investigative Site
-
Potsdam, Saksa, 14469
- Novartis Investigative Site
-
Remscheid, Saksa, 42897
- Novartis Investigative Site
-
Selters, Saksa, 56242
- Novartis Investigative Site
-
Simmern, Saksa, 55469
- Novartis Investigative Site
-
Soest, Saksa, 59494
- Novartis Investigative Site
-
Stolberg, Saksa, 52222
- Novartis Investigative Site
-
Unna, Saksa, 59423
- Novartis Investigative Site
-
Wittlich, Saksa, 54316
- Novartis Investigative Site
-
Wuppertal, Saksa, 42103
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Saksa, 79068
- Novartis Investigative Site
-
Rheinstetten, Baden-Wurttemberg, Saksa, 76287
- Novartis Investigative Site
-
-
Bavaria
-
Haßfurt, Bavaria, Saksa, 97437
- Novartis Investigative Site
-
Kulmbach, Bavaria, Saksa, 95326
- Novartis Investigative Site
-
Lauf an der Pegnitz, Bavaria, Saksa, 91207
- Novartis Investigative Site
-
Nuremberg, Bavaria, Saksa, 90402
- Novartis Investigative Site
-
-
Brandenburg
-
Panketal, Brandenburg, Saksa, 16341
- Novartis Investigative Site
-
-
Free and Hanseatic City of Hamburg
-
Hamburg, Free and Hanseatic City of Hamburg, Saksa, 22549
- Novartis Investigative Site
-
-
Lower Saxony
-
Lingen, Lower Saxony, Saksa, 49809
- Novartis Investigative Site
-
-
Mecklenburg-Vorpommern
-
Bergen auf Rügen, Mecklenburg-Vorpommern, Saksa, 18528
- Novartis Investigative Site
-
Kröpelin, Mecklenburg-Vorpommern, Saksa, 18236
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Krefeld, North Rhine-Westphalia, Saksa, 47798
- Novartis Investigative Site
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Saksa, 55128
- Novartis Investigative Site
-
-
Saxony
-
Dresden, Saxony, Saksa, 01307
- Novartis Investigative Site
-
Leipzig, Saxony, Saksa, 04207
- Novartis Investigative Site
-
Leipzig, Saxony, Saksa, 04289
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Wittenberg, Saxony-Anhalt, Saksa, 06886
- Novartis Investigative Site
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
patients, being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.
Kuvaus
Inclusion Criteria:
Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:
- Patients who provide written informed consent to participate in the study
- Male and female patients with ≥18 years of age
- Diagnosis of clinically unequivocal moderate to severe HS
- Patients for whom a therapy with secukinumab is medically indicated
- Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
- Treatment with secukinumab according to the latest version of SmPC
- Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit
Exclusion Criteria:
Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:
- Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC
- Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation
- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab
- Previous exposure to IL-17 inhibitors
- For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: PROSPECTIVE
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
secukinumab
Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication. |
Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Proportion of patients receiving up-titration
Aikaikkuna: Up to 24 months
|
Proportion of patients receiving up-titration (q4w-to-q2w) |
Up to 24 months
|
|
Proportion of patients receiving down-titration
Aikaikkuna: Up to 24 months
|
Proportion of patients receiving down-titration (q2w-to-q4w) |
Up to 24 months
|
|
Time to up-titration and down-titration
Aikaikkuna: Up to 2 years
|
Time to up-titration and down-titration |
Up to 2 years
|
|
Duration of q4w treatment with secukinumab after dose reduction
Aikaikkuna: Up to 2 years
|
Duration of q4w treatment with secukinumab after dose reduction |
Up to 2 years
|
|
Proportion of patients who receive more than one up-and/or down titration
Aikaikkuna: Up to 24 months
|
Proportion of patients who receive more than one up-and/or down titration |
Up to 24 months
|
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
Aikaikkuna: Up to 2 years
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab |
Up to 2 years
|
|
Number and type of surgical interventions
Aikaikkuna: Up to 2 years
|
Number and type of surgical interventions
|
Up to 2 years
|
|
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)
Aikaikkuna: Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
mean change of International Hidradenitis Suppurativa Severity Score System (IHS4)
Aikaikkuna: Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
Proportion of patients achieving a 5-point reduction of their Dermatology Life Quality Index (DLQI) questionnaire
Aikaikkuna: Up to 24 months
|
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment. |
Up to 24 months
|
|
Mean reduction of Abscesses and inflammatory nodules (AN) count
Aikaikkuna: Up to 24 months
|
Mean reduction of Abscesses and inflammatory nodules (AN) count |
Up to 24 months
|
|
Proportion of patients achieving a 30% reduction of pain Numerical Rating scale 30 (NRS30)
Aikaikkuna: Up to 24 months
|
The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). To assess this, the patient should concentrate on the pain that his/her skin lesions generate. The Patient's Global Assessment of Skin Pain - NRS will be completed by the subject electronically via a web-based application or in paper form. |
Up to 24 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- CAIN457MDE01
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .